Start-Up Profile: Aileron Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
Two-year old firm is developing novel peptide stapling technologies; potential initial therapeutic targets include hematological cancers.
You may also be interested in...
Roche Partners With Peptide Specialist Aileron For Five Targets
A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.
Roche Partners With Peptide Specialist Aileron For Five Targets
A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.
Aileron Therapeutics At A Glance
Business focus: novel stapled peptide drugs: peptide stapling technology stabilizes synthetic peptide